KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 89 filers reported holding KALA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 5.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $94,000 | +16.0% | 68,051 | +2.2% | 0.00% | – |
| Q4 2021 | $81,000 | -53.7% | 66,591 | -0.0% | 0.00% | – |
| Q3 2021 | $175,000 | -49.1% | 66,621 | +2.8% | 0.00% | – |
| Q2 2021 | $344,000 | -11.1% | 64,824 | +12.9% | 0.00% | -100.0% |
| Q1 2021 | $387,000 | +3.5% | 57,406 | +4.0% | 0.00% | 0.0% |
| Q4 2020 | $374,000 | -4.8% | 55,182 | +5.4% | 0.00% | 0.0% |
| Q3 2020 | $393,000 | -38.1% | 52,372 | -13.3% | 0.00% | 0.0% |
| Q2 2020 | $635,000 | +114.5% | 60,397 | +79.4% | 0.00% | 0.0% |
| Q1 2020 | $296,000 | +164.3% | 33,659 | +11.4% | 0.00% | – |
| Q4 2019 | $112,000 | +2.8% | 30,219 | +5.9% | 0.00% | – |
| Q3 2019 | $109,000 | -35.1% | 28,539 | +8.3% | 0.00% | – |
| Q2 2019 | $168,000 | +4.3% | 26,342 | +35.6% | 0.00% | – |
| Q1 2019 | $161,000 | +114.7% | 19,430 | +27.4% | 0.00% | – |
| Q4 2018 | $75,000 | -49.3% | 15,256 | +41.6% | 0.00% | – |
| Q2 2018 | $148,000 | – | 10,771 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |